Ergobyte is a market-oriented digital health SMEthat produces high quality medical software solutions. In parallel to its commercial activities, the company conducts research, focusing on the design and development of expert systems that augment human thinking.
Ergobyte's products are all offered as cloud services, exploiting a great number of advantages such as scalability, multiple service models, increased geographic reach, ease of deployment, low maintenance costs, etc. Ergobyte implements, continuously monitors and tests end-to-end security policies and measures to address the challenges related to data security and privacy.
Research and innovation are at the core of the company's corporate culture, ever since its foundation. In parallel to commercial activities, research is jointly conducted with institutes, universities and other stakeholders. Over the last ten years, Ergobyte has devoted its research efforts to design and develop intelligent systems that imitate human thinking. Its expert systems employ two crucial components: the knowledge base and the inference engine, focusing on human medication therapy and process automation within healthcare institutions.
Expert systems with interpretable reasoning, allowing the verification of produced outcomea. Inner workings are structured in a way that each result can be proven by tracing back its logical steps up to the source material.
Partner seeks Consortium/Coordinator
Digital health and AI: HORIZON-HLTH-2027-03-TOOL-08 Towards Artificial General Intelligence (AGI) for healthcare
Clinical trials: HORIZON-HLTH-2027-01-DISEASE-10 Prevention and management of chronic non-communicable diseases in children and young people (GACD)
Digital health and AI: HORIZON-HLTH-2027-03-TOOL-04 Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes